Dr. Kasper Roet is a passionate neuroscientist and entrepreneur who graduated with honors from his neuroscience master’s program at the University of Amsterdam during which he did an internship in the neural repair lab of Mark Tuszynski at UCSD and started an IT-company called Netfase. Kasper received his PhD at the Netherlands Institute for

Neuroscience and the Free University of Amsterdam in the lab of Joost Verhaagen focused on finding a treatment for spinal cord paralysis. Realizing the value of patient materials for curing diseases of the nervous system he worked for 5 years at the Netherlands Brain Bank as an adhoc autopsy team coordinator during his PhD program. To learn how to bring discoveries from bench to bedside he worked as a potency assay development team leader and technical integrator for Johnson and Johnson on a new vaccine for the paralyzing and highly contagious polio virus. Seeing the incredible discoveries stem cell modeling and gene discoveries in amyotrophic lateral sclerosis (ALS), Kasper realized that with his background in paralysis, nervous system diseases and assay development he could make a real impact for ALS patients. He decided to move to Boston with his wife and work with two world leaders in stem cell disease modeling for ALS, Harvard professors Clifford Woolf and Kevin Eggan where he developed several high throughput technologies for drug screening in ALS together with industry partners GlaxoSmithKline and Pfizer pharmaceuticals. These technologies and the discoveries at Harvard and the Boston Children’s Hospital will now be more meaningful in an industrial environment to bring new therapies to ALS patients. Therefore, together with Clifford Woolf and Kevin Eggan and Q-State Biosciences, a company that creates human patient specific models of disease that can be used in drug discovery for diseases of the nervous system, Kasper has founded QurAlis, a company focused on curing ALS, of which he is also the CEO.